Preexisting Antibodies to an F(ab′)2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment
Specificity of signal reduction in the anti-DLL4 F(ab′)2 ATA assay by different competitor molecules. Anti-DLL4 F(ab′)2 competitor will reduce all reactivity in the ATA assay. Control F(ab′)2 will not reduce anti-DLL4 F(ab′)2 CDR reactivity but will reduce F(ab′)2 framework and hinge reactivity. Anti-DLL4 full length antibody will reduce anti-DLL4 CDR and framework reactivity, but not hinge reactivity.